Skip to content

Effect of EGF With Silver Sulfadiazine Cream Compared With Silver Zinc Sulfadiazine Cream for Treatment of Burn Wound

The Clinical Efficacy of Epidermal Growth Factor With Silver Sulfadiazine Cream Compared With Silver Zinc Sulfadiazine Cream on Acceleration of Partial Thickness Burn Wound Healing

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01553708
Enrollment
34
Registered
2012-03-14
Start date
2011-12-31
Completion date
2012-05-31
Last updated
2013-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Partial Thickness Burn

Keywords

Wound healing, Epithelialization, Safety

Brief summary

Partial thickness burn wounds are most likely to heal within 2-3 weeks mainly by mechanism of epithelialization. However, it depends on the depth of the wounds and patient condition. Infection is one of the most common complications causing delay in wound healing which might affect to quality of patient's life. Generally, the standard treatment of partial thickness burn wound is topical 1% silver sulfadiazine cream. Previous studies had been reported the broad spectrum antimicrobial activity of silver sulfadiazine cream but it did not demonstrate the accelerating effect of wound healing. Therefore, the combination of substance which can promote wound healing to topical silver sulfadiazine cream might benefit for partial thickness burn wound treatment. The objective of this study was to compare the results of partial thickness burn wound treatment at burn unit, Siriraj hospital with topical cream containing 1% silver sulfadiazine plus 6% epidermal growth factor (EGF) and 1% silver zinc sulfadiazine. The demographic data (age, sex, %body surface area burn), time of wound closure, pain and itching, dose and type of pain and itching medication, adverse effect of topical medication, some laboratory results and cost of expenses. This is the prospective, double blinded, randomize-controlled study. The sample sizes were partial thickness burn wound patients who were treated at burn unit, Siriraj hospital. Patients were allocated into 2 groups receiving treatment with either topical silver sulfadiazine plus EGF or silver zinc sulfadiazine. All parameter data were analyzed with repeated measure ANOVA and independent t-test.

Interventions

DRUGEpidermal growth factor with silver sulfadiazine cream

Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)

DRUGSilver zinc sulfadiazine cream

Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)

Sponsors

National Science and Technology Development Agency, Thailand
CollaboratorOTHER_GOV
Chulalongkorn University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Aged 18-60 years. * Partial thickness burn wound more than 20%TBSA. * No underlying diseases that interfere wound healing such as chronic kidney disease, diabetes mellitus, liver disease, immunocompromised deficiency. * In case of reproductive age woman, they have to control the birth rate at least 4 weeks before study. * Patients who are willing to participate in the trial and to sign the informed consent form.

Exclusion criteria

* Immunocompromised defects * Known allergy or hypersensitivity reaction to epidermal growth factor, silver sulfadiazine or other substances in formulation. * Pregnancy or lactation

Design outcomes

Primary

MeasureTime frameDescription
Time of Healing by Monitoring Duration (Days) at the Beginning of Treatment and the Day of Completely Epithelialization (Complete Epithelialization Means no Open Wound Exists as Confirmed by Two Surgeons).On 28th day after admissionTime (days)for complete epithelialization (no open wound exists as determined by 2 surgeons) is the duration between the day of admission and the wound completely close without fluid leakage and are able to expose to environment without pain.

Secondary

MeasureTime frameDescription
Clinical Safety of Epidermal Growth Factor With Silver Sulfadiazine Cream for Treatment of Partial Thickness Burn Wound.On 28th day after admission1. Pain and itching assessment is evaluated by patients themselves in every time of wound observations using Visual Analog Scale. 2. % Wound contraction. 3. Time and type of analgesic or itching medication after treatment. 4. Laboratory measurement such as CBC, blood glucose, electrolyte, hepatic and renal functions will be analyzed to find any changes or any systemic effect after treatment. 5. Adverse reaction such as swelling, edema and redness at wound site.

Countries

Thailand

Participant flow

Recruitment details

All subjects were recruited between December 2011 to May 2012 at Burn Unit, Siriraj Hospital, Bangkok, Thailand.

Pre-assignment details

The subjects were excluded if inclusion criteria was not met or the other treatment was assigned by the physician.

Participants by arm

ArmCount
Epidermal Growth Factor With Silver Sulfadiazine Cream17
Silver Zinc Sulfadiazine Cream17
Total34

Baseline characteristics

CharacteristicSilver Zinc Sulfadiazine CreamEpidermal Growth Factor With Silver Sulfadiazine CreamTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
17 Participants17 Participants34 Participants
Age Continuous37.71 years
STANDARD_DEVIATION 7.91
37.12 years
STANDARD_DEVIATION 13.72
37.41 years
STANDARD_DEVIATION 12.41
Region of Enrollment
Thailand
17 participants17 participants34 participants
Sex: Female, Male
Female
3 Participants5 Participants8 Participants
Sex: Female, Male
Male
14 Participants12 Participants26 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 170 / 17
serious
Total, serious adverse events
0 / 170 / 17

Outcome results

Primary

Time of Healing by Monitoring Duration (Days) at the Beginning of Treatment and the Day of Completely Epithelialization (Complete Epithelialization Means no Open Wound Exists as Confirmed by Two Surgeons).

Time (days)for complete epithelialization (no open wound exists as determined by 2 surgeons) is the duration between the day of admission and the wound completely close without fluid leakage and are able to expose to environment without pain.

Time frame: On 28th day after admission

ArmMeasureValue (MEAN)Dispersion
Epidermal Growth Factor With Silver Sulfadiazine CreamTime of Healing by Monitoring Duration (Days) at the Beginning of Treatment and the Day of Completely Epithelialization (Complete Epithelialization Means no Open Wound Exists as Confirmed by Two Surgeons).23.06 DaysStandard Deviation 5.21
Silver Zinc Sulfadiazine CreamTime of Healing by Monitoring Duration (Days) at the Beginning of Treatment and the Day of Completely Epithelialization (Complete Epithelialization Means no Open Wound Exists as Confirmed by Two Surgeons).30.94 DaysStandard Deviation 7.34
Secondary

Clinical Safety of Epidermal Growth Factor With Silver Sulfadiazine Cream for Treatment of Partial Thickness Burn Wound.

1. Pain and itching assessment is evaluated by patients themselves in every time of wound observations using Visual Analog Scale. 2. % Wound contraction. 3. Time and type of analgesic or itching medication after treatment. 4. Laboratory measurement such as CBC, blood glucose, electrolyte, hepatic and renal functions will be analyzed to find any changes or any systemic effect after treatment. 5. Adverse reaction such as swelling, edema and redness at wound site.

Time frame: On 28th day after admission

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026